• Merck & Co Inc (NYSE: MRK) is reportedly mulling buying cancer-focused biotech Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported citing people familiar with the matter.

  • If the deal happens, it would be significant, given Seagen’s market value of roughly $28 billion.

  • According to the report, some people said other unnamed suitors are also eying Seagen, a perennially speculated takeover target.

  • Also Read: Amid Domestic Violence Allegation, Longtime Seagen CEO Takes Leave of Absence.

  • Talks have been underway for a while, the people said.

  • Though the people cautioned that pulling off the deal could be tricky given the heightened risk of a regulatory challenge.

  • WSJ also mentioned that a marketing agreement is also possible between Merck and Seagen.

  • Related: Read Why This Analyst Is ‘Encouraged’ By Seagen’s Q1 Sales.

  • Price Action: SGEN shares are up 13.30% at $166.26, and MRK stock is up 0.06% at $84.94 during the market session on the last check Friday.

  • Photo via Pixabay

See more from Benzinga

  • Chardan Sees Over 200% Upside On This Small-Cap Cancer-Focused Stock

  • HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications

Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

(305) 707 0888
FREE water test Quick estimate